AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01217060 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophagectomy
Description: Surgery to remove part of esophagus and nearby lymph nodes, approximately 8 to 10 weeks after completing chemoradiation.
Study NCT01217060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 10 mg IV 30 minutes prior to weekly Docetaxel.
Study NCT01475630 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: physical therapy
Description: mobilisation of the jaw, exercises, boostering information on avoiding parafunctions
Study NCT01475630 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: control
Description: relaxation
Study NCT01959542 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Study NCT01959542 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PSA Blood Test
Description: Serum PSA will also be subsequently checked on the same day as each follow-up MR is performed, i.e. TP 1, 2 and 3, and right after finishing EBRT. 1-2 mls of blood will be sampled per blood test.
Study NCT03050619 — intervention group
Intervention type: DRUG
Intervention: Empagliflozin
Study NCT03050619 — intervention group
Intervention type: DRUG
Intervention: Other SGLT2 inhibitors
Study NCT03050619 — intervention group
Intervention type: DRUG
Intervention: Other non-insulin GLDs
Description: metformin, sulfonylureas, DPP-4 inhibitors, GLP-1 agonists
Study NCT02933242 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Body Radiotherapy
Description: The total dose and number of fractions will depend on the site of disease. Treatment will be given daily, or every other day, over 1 -3 weeks
Study NCT04093778 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low dose high frequency training and Safe Delivery Phone Application
Description: The intervention period is a 9-month period where we will facilitate a quality improvement cycle using Low Dose High Frequency training with the Safe Delivery App as an anchor point and facilitate the integration into clinical practice through our Safe Delivery Focal Points at each hospital. All staff in maternity, paediatric wards and outpatient clinics will receive training and be encouraged to use the Safe Delivery App on a weekly basis.
Study NCT04780906 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wrist taping
Description: Wrist taping as used as standard in CrossFit practice
Study NCT04728269 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lactibiane Topic AD
Description: Application of Lactibiane topic AD twice a day (morning and evening) on one lesional area
Study NCT04728269 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Application of placebo twice a day (morning and evening) on the symmetrical lesional area
Study NCT02531412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: After a major surgery event a time 0, 24h and 48h
Study NCT02531412 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After a major surgery event a time 0, 24h and 48h
Study NCT04585048 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Behavioral Therapy for Selective Mutism
Description: Cognitive Behavioral treatment including 24 weekly sessions
Study NCT03933098 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Test Vaccine Vi-DT Typhoid conjugate
Description: * Manufacturer: SK Bioscience Co., Ltd.~* Ingredient: Purified Vi-polysaccharide conjugated to diphtheria toxoid~* Dose: 25 µg of Vi polysaccharide/0.5 mL, presented in 3 mL multi-dose glass vial
Study NCT02732834 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: patients will fill out a questionnaire about their perceived stigma, satisfaction with communication, and psychological distress.
Study NCT02732834 — intervention group
Intervention type: BEHAVIORAL
Intervention: Patient Interview
Description: Then they will participate in a brief in-person interview about their perceived stigma during the clinical consultation
Study NCT02732834 — intervention group
Intervention type: BEHAVIORAL
Intervention: Audio recordings of clinical consultations
Study NCT04492514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavrilimumab
Description: Treatment infusion
Study NCT04492514 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo infusion
Study NCT02732834 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Patients will fill out a questionnaire about their perceived stigma and satisfaction with their clinician's communication.
Study NCT02843282 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advanced Reasoning Training
Description: This is a strategy-based intervention to enhance frontal lobe function. Strategies equip participants to improve their strategic attention, integrated reasoning, and innovation abilities.
Study NCT04008173 — intervention group
Intervention type: OTHER
Intervention: Non-interventional patient registry
Description: Non-interventional patient registry
Study NCT00610922 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA)
Description: DHA 20 mg per day through 12 months of life
Study NCT03234023 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: INTERVENTION GROUP
Description: Offer recommendations of healthy living habits and control of pharmacy administration
Study NCT03270280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nigella Sativa Oil
Description: The individuals will apply 55 drops of Nigella sativa Oil on gingivae twice daily for two weeks
Study NCT03270280 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: The individuals will apply 55 drops of Normal saline on gingivae twice daily for two weeks
Study NCT00756379 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive therapy program for risk factor modification
Description: Patients enrolled in the comprehensive therapy arm will have a baseline myocardial perfusion PET and the support of a team of professionals aiming to modify and minimize all the known CAD risk factors. During the 5 year follow-up they will be educated and guided toward a healthy lifestyle by a dietician, an exercise physiologist/cardiovascular physician specialist.
Study NCT04212026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: The patients start treatment with nivolumab on day 1 after IRE and will be given nivolumab at a flat dose of 240 mg every 2 weeks (q2wk) for 5 cycles until Week 8.
Study NCT03933098 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Vaccine Typbar TCV®
Description: * Manufacturer: Bharat Biotech~* Ingredient: Purified Vi capsular polysaccharide of Salmonella Ty2 conjugated to tetanus toxoid protein~* Dose: 0.5 ml
Study NCT00411892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone
Description: Tablets, 45 mg/day.
Study NCT00411892 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pioglitazone
Description: Tablets, 45 mg/day.
Study NCT00411892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled human insulin
Description: Treat-to-target dose titration scheme, inhalation.
Study NCT03688191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Patients will receive oral sirolimus at a starting dose of 2 mg per day for 3 days and a sequential dose of 1mg per day, with dose adjusted according to tolerance and to maintain a therapeutic range of 6-15 ng/mL.
Study NCT01024816 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Restorative yoga
Description: Group yoga sessions: Participants will attend 90 minute yoga group classes for 48 weeks: twice a week for 6 weeks, then once weekly during weeks 7 to 12, then every other week for weeks 13 - 24, and once a month for 6 months. We plan a progressive series of classes, with a subset of poses for each class and then selecting individual poses to focus on in each class.~Home yoga practice: Participants will be given a video disk (DVD) of the yoga postures at the start of the yoga intervention practice. We will also provide the yoga participants with a written manual with pictures and descriptions of each posture that they will be taught in the group sessions. The participants will be asked to practice the postures taught during their group sessions at home at least three times a week with the assistance of the DVD and manual. Each participant will be given a set of yoga props for their use at home. We will ask all participants to keep a log of their home practice sessions
Study NCT01024816 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching
Description: Group classes: Participants will attend 90 minute group stretching classes for 48 weeks: twice a week for 6 weeks, then once weekly during weeks 7 to 12, then every other week for weeks 13 - 24, and once a month for 6 months. The stretches will address all body parts, including cervical, upper extremity, thoracic, lumbar, pelvic, and lower extremity musculature.~Home stretching practice: Each participant will receive a written manual with pictures and descriptions of each stretch that they will be learning in group sessions and a DVD with instruction on each of the stretches. The participants will be asked to practice the stretches taught during their group sessions at home at least three times a week with the assistance of the DVD and manual. Each participant will be given stretching supplies. We will ask all participants to keep a log of their home practice sessions.
Study NCT02556801 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: SUBLIVAC FIX Phleum Prat.
Description: sublingual daily administration
Study NCT02556801 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SUBLIVAC FIX Phleum Prat.
Description: sublingual daily administration
Study NCT01109446 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma
Description: 27ml of autologous whole blood added to 3ml of ACD-A (Citrate Anticoagulant). After separation of the platelets, a high concentration of platelets (3-4ml Platelet Rich Plasma) is injected into the tendon through 7 perforations of the tendon, guided by ultrasound.
Study NCT01109446 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Isotonic Saline Solutions
Description: 3ml of Isotonic Saline Solution is injected into the tendon through 7 perforations of the tendon, guided by ultrasound.
Study NCT01109446 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolonacetonid
Description: Triamcinolonacetonid 40mg/ml. 40mg of Triamcinolonacetonid is mixed with 2ml of Lidocaine 10mg/ml. It is injected deep into the tendon, guided by ultrasound.
Study NCT00390039 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV Placebo q3h PRN
Study NCT00390039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal morphine
Description: MNS075 15mg q3h PRN
Study NCT00390039 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IN Placebo q3h PRN
Study NCT00006773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study NCT04262076 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulpine with Polyamidoamine Dendrimer
Description: Removal of infected dentin in class I Cavities followed by application of Polyamidoamine Denrimer on caries affected Dentin that is washed out of the cavity after 30 secs then finally place Pulpine .
Study NCT04262076 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulpine with Polyamidoamine Dendrimer
Description: Removal of infected dentin in class I Cavities followed by application of Polyamidoamine Denrimer on caries affected Dentin that is washed out of the cavity after 30 secs then finally place Pulpine .
Study NCT00448747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEZS-130 (formerly ARD-07)
Description: A single oral administration of AEZS-130 as Growth Hormone Stimulation Test
Study NCT00448747 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-ARG+GHRH
Description: A single administration of L-ARG+GHRH (iv bolus) followed by a 30min infusion of L-ARG as Growth Hormone Stimulation Test
Study NCT04256681 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SNAP questionnaire
Description: The SNAP questionnaire will be administered 2 times in 2 consecutive days to evaluate its reliability. The questionnaire will be self-filled by the patient. Then the SPRS scale and, where possible, the 6MWT will be administered.
Study NCT04256681 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SNAP questionnaire
Description: The SNAP questionnaire will be administered 2 times in 2 consecutive days to evaluate its reliability. The questionnaire will be self-filled by the patient. Then the SPRS scale and, where possible, the 6MWT will be administered.
Study NCT03421912 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cicaplast Balm B5
Description: The patients have to do 2 to 3 applications per day on the face, on lesions and in poultice in the evening in case of painful crack on the fingers
Study NCT03421912 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dexeryl
Description: The patients have to do 2 to 3 applications per day on the face, on lesions and in poultice in the evening in case of painful crack on the fingers
Study NCT02272712 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy
Description: psychoeducation about insomnia, relaxation training, sleep restriction, stimulus control, hypnotic tapering under direction of a physician, cognitive therapy, sleep hygiene
Study NCT03592485 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane blockade
Description: Before the beginning of the procedure, ESP blockade will be performed under ultrasound control. A single-shot technique will be used with 0.375 % solution of ropivacaine: 0.1 mL per patients' KG. The maximum dose is 20 mL.
Study NCT03592485 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pectoral Fascia block
Description: Before the beginning of the procedure, PECS type I and II blocks will be performed under ultrasound control. A single-shot technique will be used with 0.375 % solution of ropivacaine: 0.1 mL per patients' KG. The maximum dose is 20 mL.
Study NCT03592485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Each patient, before the end of surgery, will be administered i.v. 0.1 mg of oxycodone. PCA with oxycodone (1mg/mL) will be utilized during the postoperative period: 5-minute interval.
Study NCT04011514 — intervention group
Intervention type: BEHAVIORAL
Intervention: Dedicated stroke nurse care in ED
Description: A specialized SU nursing team partner with ED nursing staff for timely fulfillment of stroke quality care indicators while awationg admission to a dedicated stroke unit
Study NCT03592485 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: general anesthesia
Description: Each patient will generally anesthetized and endotracheal tube will be inserted
Study NCT02275169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Urofollitropin
Description: Urofollitropin 75 IU 2 ampoules three times a week for three months
Study NCT02275169 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo ampoules administered three times a week for three months
Study NCT06275438 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The delivery being performed via cesarean section surgery rather than natural childbirth
Description: At Kars Harakani State Hospital and Kafkas University, 16 placentas were collected, with 8 obtained from induced deliveries and 8 from spontaneous deliveries, between 09:00-21:00. Nulliparity and multiparity were not distinguished among the expectant mothers. Placentas were obtained hours before delivery from mothers admitted to the gynecology service, whose eligibility was determined based on exclusion criteria, after obtaining signed informed consent forms, with assurances given that no interventional procedures would be performed on the mother or the baby. The method of cesarean section (spinal or general anesthesia) in the case group was recorded, ensuring that the anesthetic agents used contained the same active ingredients. Placentas from births involving different anesthetic drugs were not included in the study, aiming to standardize the procedure.
Study NCT03592485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol
Description: Paracetamol will be given i.v. every 6 hours.
Study NCT01836302 — intervention group
Intervention type: OTHER
Intervention: Observation
Study NCT03112655 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: RNA and neopterin detection
Description: Detection of spliced leader RNA will be performed on blood and cerebrospinal fluid taken before treatment, 11 days after treatment, 6, 12 and 18 months after treatment. Neopterin and 5-hydroxytryptophan will be quantified in cerebrospinal fluid taken at the same time points.
Study NCT02120391 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iPhone Application
Description: All subjects will receive the iPhone App on their phone however not all subjects will have the intervention (medication notifications) turned on.
Study NCT02120391 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: iPhone Application
Description: All subjects will receive the iPhone App on their phone however not all subjects will have the intervention (medication notifications) turned on.
Study NCT04467281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-DFO-daratumumab
Description: Patients will undergo 89Zr-DFO-daratumumab PET/CT once before standard of care therapy and once again afterward, for a total of two research scans.
Study NCT04467281 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: Patients will undergo 89Zr-DFO-daratumumab PET/CT once before standard of care therapy and once again afterward, for a total of two research scans.
Study NCT03724318 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: closure of the left atrium appendage
Description: closure of the left atrium appendage in addition to the planned Heart operation
Study NCT01277757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt Inhibitor MK2206
Description: Given orally (PO) weekly, starting (dose 0) at 200 mg
Study NCT01277757 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01277757 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT00556088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589, Paclitaxel, Carboplatin, Bevacizumab
Description: LBH589 will be administered orally twice weekly. Paclitaxel and carboplatin will be administered intravenously every 21 days.~Once the MTD is established, drug dosages will be adjusted downward by one dose level and bevacizumab 15mg/kg intravenously every 3 weeks will be administered to a subset of patients with non-small cell lung cancer.
Study NCT02432027 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: C-82 Topical Gel, Placebo
Description: placebo
Study NCT02432027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C-82 Topical Gel, 1%
Description: active
Study NCT02432027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daivonex cream
Description: comparator
Study NCT02489383 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Exercise Training
Description: The continuous training (CT) will be held in two weekly sessions lasting total of 40 minutes and 5 minutes for heating and 5 to slowdown, and the duration will be 24 sessions (3 months). The exercise sessions will be will be performed on a stationary bicycle, with the initial intensity of 70% of VO2max. If the subject sustain continuously training intensity for 2 consecutive sessions without symptoms breathing, exercise intensity will be increased by 5% of heart rate. The patient may stop the activity if he has any symptoms or respiratory distress, returning it as soon present improvement. Throughout the training, will be monitored heart rate and the level of perception subjective effort (modified Borg scale).
Study NCT02489383 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interval Exercise Training
Description: The interval training (IT) will be held in two weekly sessions. The IT is individualized and will be performed on a stationary bicycle. Training sessions will be performed with total duration of 40 minutes consisting of 5 minutes extender, 30 minutes from the main part (IT), finishing with five minutes back to calm. In the main part (of 5 to 30 minutes), the patient will perform the exercise with high intensity in the first two weeks, the exercise will be conducted with an intensity 80% of maximum capacity obtained in cycle ergometer test and will cycle for 30 seconds followed by a 30 second recovery period. In the 3rd and 4th weeks, the intensity will be increased to 100% of the maximum obtained. After this period, the intensity will be increased by 5% charge.
Study NCT02432027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diprosis gel
Description: comparator
Study NCT01733394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine Generic A Lamotrigine Generic B Lamotrigine Brand